Results

Biophytis SA

07/01/2020 | Press release | Distributed by Public on 07/01/2020 15:25

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

01 Jul 2020 21:05 CEST

Company Name

BIOPHYTIS

ISN

FR0012816825

Market

Euronext Growth

Symbol

ALBPS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_934579_Biophytis__COVA_FDA_IND_Clearance__PR_EN_vF_.pdf

Source

BIOPHYTIS

Provider

Les Echos